[
  {
    "ts": "2025-12-19T14:51:15+00:00",
    "headline": "Pfizer (PFE) CEO’s Struggling Because Of “a Good Hand,” Says Jim Cramer",
    "summary": "We recently published 12 Stocks on Jim Cramer’s Radar. Pfizer Inc. (NYSE:PFE) is one of the stocks on Jim Cramer’s radar. Pfizer Inc. (NYSE:PFE)’s shares are down by 5.90% year-to-date, and December has been a tumultuous month for them. On Tuesday, the stock dipped by 5.2% after the firm released its full-year 2026 guidance. The […]",
    "url": "https://finance.yahoo.com/news/pfizer-pfe-ceo-struggling-because-145115350.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "4fac2f94-3f6f-3573-b0e3-ed6389315d36",
      "content": {
        "id": "4fac2f94-3f6f-3573-b0e3-ed6389315d36",
        "contentType": "STORY",
        "title": "Pfizer (PFE) CEO’s Struggling Because Of “a Good Hand,” Says Jim Cramer",
        "description": "",
        "summary": "We recently published 12 Stocks on Jim Cramer’s Radar. Pfizer Inc. (NYSE:PFE) is one of the stocks on Jim Cramer’s radar. Pfizer Inc. (NYSE:PFE)’s shares are down by 5.90% year-to-date, and December has been a tumultuous month for them. On Tuesday, the stock dipped by 5.2% after the firm released its full-year 2026 guidance. The […]",
        "pubDate": "2025-12-19T14:51:15Z",
        "displayTime": "2025-12-19T14:51:15Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/ddb91ea345a3caa2bed91df10c8995bd",
          "originalWidth": 1920,
          "originalHeight": 1272,
          "caption": "Pfizer (PFE) CEO's Struggling Because Of \"a Good Hand,\" Says Jim Cramer",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/FX7iP5u5zmCV2jrzGOzvvA--~B/aD0xMjcyO3c9MTkyMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/insidermonkey.com/ddb91ea345a3caa2bed91df10c8995bd.cf.webp",
              "width": 1920,
              "height": 1272,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MYWwqgyghHg1GWNVfa79RA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/ddb91ea345a3caa2bed91df10c8995bd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-pfe-ceo-struggling-because-145115350.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-pfe-ceo-struggling-because-145115350.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-19T14:50:22+00:00",
    "headline": "Jim Cramer Couldn’t Stop Gushing About Johnson & Johnson (JNJ)’s Cancer Drugs",
    "summary": "We recently published 12 Stocks on Jim Cramer’s Radar. Johnson & Johnson (NYSE:JNJ) is one of the stocks on Jim Cramer’s radar. Healthcare giant Johnson & Johnson (NYSE:JNJ) factored into the discussion after Cramer and his co-hosts discussed Pfizer and Merck. The firm’s shares are up by 46% year-to-date and have had a good December […]",
    "url": "https://finance.yahoo.com/news/jim-cramer-couldn-t-stop-145022789.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "ab2a1f66-2aed-3a18-891f-47fc1234232a",
      "content": {
        "id": "ab2a1f66-2aed-3a18-891f-47fc1234232a",
        "contentType": "STORY",
        "title": "Jim Cramer Couldn’t Stop Gushing About Johnson & Johnson (JNJ)’s Cancer Drugs",
        "description": "",
        "summary": "We recently published 12 Stocks on Jim Cramer’s Radar. Johnson & Johnson (NYSE:JNJ) is one of the stocks on Jim Cramer’s radar. Healthcare giant Johnson & Johnson (NYSE:JNJ) factored into the discussion after Cramer and his co-hosts discussed Pfizer and Merck. The firm’s shares are up by 46% year-to-date and have had a good December […]",
        "pubDate": "2025-12-19T14:50:22Z",
        "displayTime": "2025-12-19T14:50:22Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/0de803e1886e8570c453e6c179672b53",
          "originalWidth": 1000,
          "originalHeight": 668,
          "caption": "Jim Cramer Couldn't Stop Gushing About Johnson & Johnson (JNJ)'s Cancer Drugs",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.1i2Xg8sqkYBwxzkIAC02w--~B/aD02Njg7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/0de803e1886e8570c453e6c179672b53.cf.webp",
              "width": 1000,
              "height": 668,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MUHt2SWlA2SDsXLMEXhTeg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/0de803e1886e8570c453e6c179672b53.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/jim-cramer-couldn-t-stop-145022789.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/jim-cramer-couldn-t-stop-145022789.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-19T09:30:00+00:00",
    "headline": "Down 80%, Should You Buy the Dip on Moderna?",
    "summary": "Your decision on whether to invest now depends to some extent on your investment strategy.",
    "url": "https://www.fool.com/investing/2025/12/19/down-80-should-you-buy-the-dip-on-moderna/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "e406e15c-f46a-3c6f-891f-153addcaf7e4",
      "content": {
        "id": "e406e15c-f46a-3c6f-891f-153addcaf7e4",
        "contentType": "STORY",
        "title": "Down 80%, Should You Buy the Dip on Moderna?",
        "description": "",
        "summary": "Your decision on whether to invest now depends to some extent on your investment strategy.",
        "pubDate": "2025-12-19T09:30:00Z",
        "displayTime": "2025-12-19T09:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/1cadddbdf61f5428bcd51ff178dd39e9",
          "originalWidth": 1200,
          "originalHeight": 800,
          "caption": "An investor looks pensively at a laptop screen at home.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/durqZJ1rlVd.d6npOlKK2w--~B/aD04MDA7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/1cadddbdf61f5428bcd51ff178dd39e9.cf.webp",
              "width": 1200,
              "height": 800,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/dTcmh8yHlpiAfzh.UYZmKQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/1cadddbdf61f5428bcd51ff178dd39e9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/12/19/down-80-should-you-buy-the-dip-on-moderna/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/down-80-buy-dip-moderna-093000960.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRNA"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-19T04:33:54+00:00",
    "headline": "1 S&P 500 Stock with Impressive Fundamentals and 2 That Underwhelm",
    "summary": "While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.",
    "url": "https://finance.yahoo.com/news/1-p-500-stock-impressive-043354556.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "bab04e04-b1e7-3e99-b8c5-63f8e66b52cd",
      "content": {
        "id": "bab04e04-b1e7-3e99-b8c5-63f8e66b52cd",
        "contentType": "STORY",
        "title": "1 S&P 500 Stock with Impressive Fundamentals and 2 That Underwhelm",
        "description": "",
        "summary": "While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.",
        "pubDate": "2025-12-19T04:33:54Z",
        "displayTime": "2025-12-19T04:33:54Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/c33d5012ea1701a7be34c00d3064b11a",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "AVGO Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/n3Ln7U_MFdIYf7_witPBbA--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/c33d5012ea1701a7be34c00d3064b11a.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/mtUV7bXykTIqoQWBHdxzAA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/c33d5012ea1701a7be34c00d3064b11a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/1-p-500-stock-impressive-043354556.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/1-p-500-stock-impressive-043354556.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "AVGO"
            },
            {
              "symbol": "ALL"
            },
            {
              "symbol": "ALL-PH"
            },
            {
              "symbol": "ALL-PI"
            },
            {
              "symbol": "ALL-PJ"
            },
            {
              "symbol": "VTRS"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-19T01:50:00+00:00",
    "headline": "3 Absurdly Cheap Stocks You Can Buy For Less than $100 Right Now",
    "summary": "The stocks listed here trade at forward earnings multiples of less than 18.",
    "url": "https://www.fool.com/investing/2025/12/18/3-absurdly-cheap-stocks-you-can-buy-for-less-than/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "1cc4b0c9-2111-346c-8ca7-23c082c2a920",
      "content": {
        "id": "1cc4b0c9-2111-346c-8ca7-23c082c2a920",
        "contentType": "STORY",
        "title": "3 Absurdly Cheap Stocks You Can Buy For Less than $100 Right Now",
        "description": "",
        "summary": "The stocks listed here trade at forward earnings multiples of less than 18.",
        "pubDate": "2025-12-19T01:50:00Z",
        "displayTime": "2025-12-19T01:50:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/3b7f4cc4db694a851507571137a9bcc1",
          "originalWidth": 1400,
          "originalHeight": 933,
          "caption": "A person in business clothing checks a smartphone.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/EwNRHFGWIxTwbDxdeybkGQ--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/3b7f4cc4db694a851507571137a9bcc1.cf.webp",
              "width": 1400,
              "height": 933,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hB8Q_CP0ba4ZTw9muy5qwg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/3b7f4cc4db694a851507571137a9bcc1.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/12/18/3-absurdly-cheap-stocks-you-can-buy-for-less-than/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/3-absurdly-cheap-stocks-buy-015000947.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AZN"
            },
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "CVS"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-19T11:01:21+00:00",
    "headline": "Novo files for CagriSema approval; Merck and Pfizer’s trial win",
    "summary": "Novo Nordisk's application for CagriSema comes at the same time as competitor Eli Lilly's ask for its obesity drug orforglipron. Elsewhere, Merck & Co. and Pfizer succeeded in a bladder cancer trial",
    "url": "https://www.biopharmadive.com/news/novo-cagrisema-merck-pfizer-keytruda-padcev-gsk/808142/",
    "source": "BioPharma Dive",
    "provider": "yfinance",
    "raw": {
      "id": "381d876d-019f-355f-95ed-426d2c5d943c",
      "content": {
        "id": "381d876d-019f-355f-95ed-426d2c5d943c",
        "contentType": "STORY",
        "title": "Novo files for CagriSema approval; Merck and Pfizer’s trial win",
        "description": "",
        "summary": "Novo Nordisk's application for CagriSema comes at the same time as competitor Eli Lilly's ask for its obesity drug orforglipron. Elsewhere, Merck & Co. and Pfizer succeeded in a bladder cancer trial",
        "pubDate": "2025-12-19T11:01:21Z",
        "displayTime": "2025-12-19T11:01:21Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/biopharma_dive_768/e36d70a3849ea73409df7aca9613c259",
          "originalWidth": 1600,
          "originalHeight": 900,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YSECyFvzK8sIEiUW4LIicA--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/biopharma_dive_768/e36d70a3849ea73409df7aca9613c259.cf.webp",
              "width": 1600,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/heEgXBvKL8Y58FXAXGaXPg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/biopharma_dive_768/e36d70a3849ea73409df7aca9613c259.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "BioPharma Dive",
          "url": "https://biopharmadive.com/"
        },
        "canonicalUrl": {
          "url": "https://www.biopharmadive.com/news/novo-cagrisema-merck-pfizer-keytruda-padcev-gsk/808142/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-files-cagrisema-approval-merck-110121453.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "CAMP"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]